CoChat

Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.

Open access
Isaacs, John D, Harari, Olivier, Kobold, Uwe, Lee, Janet S, Bernasconi, Corrado · 2013 · Arthritis Research & Therapy

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Our objective was to determine the interrelationships of interleukin (IL)-6 receptor inhibition with haemoglobin, acute-phase reactants and iron metabolism markers (including hepcidin) in patients with rheumatoid arthritis (RA). METHODS: Data of patients receiving tocilizumab or placebo in the MEASURE study were analysed. We investigated associations at baseline and during tocilizumab treatment among haemoglobin, parameters of haemoglobin and iron homeostasis [ferritin, total iron-binding capacity (TIBC), hepcidin, haptoglobin], IL-6 and acute-phase reactants [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] to identify statistical correlates of rise in haemoglobin level. RESULTS: At baseline, CRP and haptoglobin were inversely correlated (modestly) with haemoglobin levels. After treatment with tocilizumab, CRP, hepcidin, ferritin and haptoglobin levels fell alongside increases in TIBC and haemoglobin. The falls in CRP, hepcidin and haptoglobin levels in the first 2 weeks correlated with a week 12 rise in TIBC and haemoglobin. CONCLUSIONS: Inflammatory anaemia improves in patients with RA treated with tocilizumab. This improvement correlates with the degree of suppression of systemic inflammation, reduction in hepcidin and haptoglobin and increase in iron-binding capacity. These clinical data provide evidence of a role for IL-6 signalling in the inflammatory anaemia of RA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/ar4397

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Time course of median percentage change in (A) haematological and (B) inflammatory markers. Patients received tocilizumab + MTX. TIBC, total iron-binding capacity. MTX, methotrexate.
Figure 1 Time course of median percentage change in (A) haematological and (B) inflammatory markers. Patients received tocilizumab + MTX. TIBC, total iron-binding capacity. MTX, methotrexate.CC BY · PubMed Central
Figure 2 Scatter plot and linear regression of haemoglobin level at week 12 versus log hepcidin. Change from baseline in haemoglobin level (g/dl) at week 12 versus mean of change from baseline at weeks 1 and 2 in log hepcidin (fmol/μL). (A) Placebo: r2 = 0.002; P = 0.76; Spearman rank correlation: ρ = 0.04, P = 0.79. (B) Tocilizumab: r2 = 0.09; P = 0.012; Spearman rank correlation: ρ = -0.35, P = 0.005. aMean of weeks 1 and 2 assessments.
Figure 2 Scatter plot and linear regression of haemoglobin level at week 12 versus log hepcidin. Change from baseline in haemoglobin level (g/dl) at week 12 versus mean of change from baseline at weeks 1 and 2 in log hepcidin (fmol/μL). (A) Placebo: r2 = 0.002; P = 0.76; Spearman rank correlation: ρ = 0.04, P = 0.79. (B) Tocilizumab: r2 = 0.09; P = 0.012; Spearman rank correlation: ρ = -0.35, P = 0.005. aMean of weeks 1 and 2 assessments.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 2

  1. McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: MEASURE: a translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation [abstract]. Ann Rheum Dis. 2011, 70 ((suppl)): 73-
  2. McInnes IB, Lee JS, Wu W, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Delles C, Sattar N: Lipid and inflammation parameters: a translational, randomized placebo-controlled study to evaluate effects of tocilizumab: the MEASURE study. 2011, Chicago, IL: Presented at: 75th Annual Scientific Meeting of the American College of Rheumatology

Cited by

Metadata

Authors
Isaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C.
Affiliations
  • Newcastle University (GB)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Isaacs, John D
Venue
Arthritis Research & Therapy
Published
2013-12-02
Volume
15
Issue
6
Pages
R204-R204
ISSN
1478-6354 (ISSN-L)
OpenAlex
W2114448779
Cited by
105
References
17
Citations by year
2026: 6 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 10 · 2021: 18 · 2020: 16 · 2019: 10 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 3 · 2014: 3
FWCI
3.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Arthritis Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
F. Hoffmann-La Roche
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Keywords
tocilizumab, rheumatoid arthritis, IL-6 receptor inhibition, hepcidin, haptoglobin, ferritin, total iron binding capacity, iron metabolism, hemoglobin, C-reactive protein, acute phase proteins, systemic inflammation
MeSH terms
Adult, Aged, Anemia, Arthritis, Rheumatoid, Double-Blind Method, Female, Haptoglobins, Hemoglobins, Humans, Male, Middle Aged, Signal Transduction, Biomarkers, Interleukin-6, Antibodies, Monoclonal, Humanized, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.